After a few pain medications didn’t work, he was eventually referred to a rheumatologist who provided a more accurate diagnosis: Psoriatic arthritis, a chronic condition marked by joint pain and skin ...

in adults with psoriatic arthritis (PsA). The APEX trial has been comparing the drug against placebo in patients with active PsA who are biologic naïve and have had an inadequate response to standard ...

Initially disclosing a diagnosis of rheumatoid arthritis, he later revealed that he actually suffers from psoriatic arthritis - a chronic condition characterised by joint pain, swelling and ...

Adam also apologised to his followers for having not been "very vocal" about his experience with arthritis lately. He told them in the recent post on Instagram: "[I'm] just struggling and trying ...

of reducing signs and symptoms and its major secondary endpoint of reducing progression of structural damage measured by radiographic progression at 24 weeks, in adults living with active psoriatic ...

US-based pharmaceutical company Johnson & Johnson (J&J) has reported positive results from a Phase IIIb trial of its monoclonal antibody Tremfya (guselkumab) for active psoriatic arthritis (PsA).

For approximately 85% of patients diagnosed with psoriatic arthritis, the skin manifestations of psoriasis emerge first, with joint symptoms typically developing 7-10 years after initial skin ...

Patients with psoriatic arthritis (PsA) experienced longer diagnostic delays than matched patients with rheumatoid arthritis (RA). Patients with polyarticular PsA received less intensive disease ...

for active psoriatic arthritis (PsA). The APEX trial met both its primary and major secondary endpoints at 24 weeks in adults with active PsA. The double-blind, multi-centre trial showed that the ...

Johnson & Johnson (NYSE:JNJ) on Friday announced topline results from Phase 3b APEX study of Tremfya (guselkumab) in patients with active psoriatic arthritis ... of reducing signs and symptoms ...

TREMFYA ® demonstrated clinically meaningful and statistically significant efficacy in patients with active psoriatic arthritis at risk for structural damage in Phase 3b study Topline results ...